This year’s American Society of Clinical Oncology conference (ASCO), held in Chicago in June, produced a number of interesting and informative GIST-relevant presentations. Below is an overview and we will be posting the rest of the articles very soon.
Results of the Scandinavian Sarcoma Group (SSG 18) adjuvant imatinib (Gleevec/Glivec) trial in high risk GIST were presented on June 5, during the Plenary Session of the 2011 American Society of Clinical Oncology conference (ASCO). The Plenary or “all members’ session” highlights “abstracts deemed to have the highest merit and greatest impact on oncology research and practice”.
